Item(by='mlyle', descendants=None, kids=None, score=None, time=1607729644, title=None, item_type='comment', url=None, parent=25391045, text='&gt; and one of them went to someone with self-admittedly &quot;very mild symptoms,&quot;<p>In fairness, the monoclonal antibodies have been shown to be ineffective when given by the point symptoms are severe.  To save any lives, you&#x27;ll need to give them to people with mild to moderate symptoms but significant risk factors.<p>e.g. &quot;...Casirivimab and imdevimab are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation....&quot; <a href="https:&#x2F;&#x2F;www.fda.gov&#x2F;news-events&#x2F;press-announcements&#x2F;coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19" rel="nofollow">https:&#x2F;&#x2F;www.fda.gov&#x2F;news-events&#x2F;press-announcements&#x2F;coronavi...</a><p>Of course, this really sucks, because there&#x27;s nowhere near enough to give to everyone who&#x27;s high risk and has early COVID, while there might eventually be enough to give to people with severe COVID.')